Project Details
| Acronym | JNJ-80954385LYM1001 |
|---|---|
| Status | Active |
| Effective start/end date | 6/09/22 → 8/08/27 |
CTU: A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL
- Di Ciaccio, Pietro (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Chester, Catherine (Clinical Trial Unit Staff)
Project: Research